Shingles Vaccine Market Analysis Report 2025: Market to Grow by a CAGR of 9.1 to 2033, Driven by Government Incentives, Popularity of Virtual Assistants, and Strategic Partnerships

Key Insights

The Shingles Vaccine Market size was valued at USD 5.7 USD Billion in 2023 and is projected to reach USD 10.49 USD Billion by 2032, exhibiting a CAGR of 9.1 % during the forecast period. The shingles vaccine is recommended for patients over 50 years of practice to prevent herpes zoster, a skin condition that is associated with an agonizing sting due to the re-emergence of the varicella-zoster virus. There are two main types of shingles vaccines: Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV) both can be used. ZVL is in the form of a live attenuated vaccine that works by using weakened virus strains to trigger the immune system while, RZV uses inactivated viruses’ proteins to initiate an immune response. Some of the qualities of these vaccines include the ability to prevent the occurrence of shingles, and the ability to lessen the severity of its symptoms. ZVL is taken once while RZV is taken in two doses. Older individuals are encouraged to take the vaccines because the incidence of shingles rises with age. They are critical in order to avoid the conditions related to the disease, for instance, postherpetic neuralgia. 

Shingles Vaccine Trends

• Increasing prevalence of herpes zoster due to the aging population
• Growing awareness about the benefits of shingles vaccines
• Favorable government initiatives to promote vaccination

Driving Forces: What's Propelling the Shingles Vaccine Market

• Aging population: The population aged 50 and older is the most vulnerable to shingles, and the number of individuals in this age group is growing rapidly worldwide. This aging population represents a significant driving force for the shingles vaccine market.
• Increased disease burden: Shingles is a painful and debilitating condition that can lead to serious complications. The rising incidence of shingles and associated healthcare costs are contributing to the demand for preventive measures such as vaccination.
• Rising awareness: Public health campaigns and educational initiatives have played a crucial role in raising awareness about the importance of shingles vaccines and their benefits. This increased awareness has led to growing demand for vaccination.
• Favorable government initiatives: Governments across the globe are recognizing the importance of shingles prevention and are implementing initiatives such as free or subsidized vaccination programs. These initiatives aim to increase access to vaccines and reduce the disease burden.
• Technological advancements: The development of new and improved shingles vaccines, such as high-efficacy recombinant zoster vaccines, is further driving the market growth.

Challenges and Restraints in Shingles Vaccine Market

• High Cost and Accessibility Barriers: The significant cost of shingles vaccines presents a substantial financial hurdle for many individuals, particularly those without comprehensive health insurance coverage. This cost barrier disproportionately impacts vulnerable populations and limits widespread vaccine uptake. Furthermore, access remains a significant challenge, especially in developing countries with limited healthcare infrastructure and strained healthcare budgets, leading to inequitable access to this crucial preventative measure.
• Safety Concerns and Adverse Events: While generally safe and effective, shingles vaccines can cause mild to moderate side effects in some recipients, including pain, redness, swelling, and fatigue at the injection site. These potential adverse events, even if infrequent, can contribute to vaccine hesitancy and impact vaccination rates. Transparency and proactive communication regarding potential side effects are crucial to address these concerns and build public trust.
• Suboptimal Vaccination Rates and Public Awareness: Despite the availability of effective shingles vaccines, vaccination rates remain significantly lower than recommended levels. This is partly due to insufficient public awareness of the disease burden and the benefits of vaccination. Increased public health campaigns, targeted education initiatives, and physician recommendations are needed to improve vaccination uptake and protect at-risk populations. Additionally, the relatively recent introduction of shingles vaccines means long-term efficacy data are still being collected, which further impacts adoption.
• Evolving Regulatory Landscape and Reimbursement Policies: The regulatory landscape surrounding shingles vaccines is constantly evolving, with varying approval processes and reimbursement policies across different countries. Navigating these complexities can pose challenges for manufacturers and healthcare providers, impacting market access and vaccine availability.

Emerging Trends in Shingles Vaccine

• Development of new shingles vaccines with improved efficacy and safety profiles
• Increasing use of adjuvants to enhance vaccine immunogenicity
• Development of combination vaccines that protect against shingles and other diseases

Growth Catalysts in Shingles Vaccine Industry

• Government initiatives to promote vaccination
• Increasing awareness about the benefits of shingles vaccines
• Development of new and more effective vaccines

Market Segmentation: Shingles Vaccine Analysis

Drug:

• Zostavax
• Shingrix
• Others

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Leading Players in the Shingles Vaccine Market

• Merck & Co., Inc.
• GlaxoSmithKline plc
• SK Bioscience
• Pfizer Inc.
• Sanofi Pasteur
• Seqirus
• Mitsubishi Tanabe Pharma Corporation
• Johnson & Johnson
• Emergent BioSolutions
• Takeda Pharmaceutical Company Limited
• Novavax

Significant Developments in the Shingles Vaccine Sector

• In 2022, Merck & Co. announced that its Shingrix vaccine was approved by the U.S. Food and Drug Administration (FDA) for use in adults 50 years of age and older.
• In 2021, GlaxoSmithKline plc announced that its Zostavax vaccine was approved by the European Medicines Agency (EMA) for use in adults 50 years of age and older.

Comprehensive Coverage Shingles Vaccine Market Report

• Market Sizing and Segmentation: In-depth analysis of the global shingles vaccine market size, growth rate, and key market segments, including by vaccine type, age group, and geographic region, providing valuable insights into market dynamics.
• Competitive Landscape Analysis: Identification of the leading players in the market, their market share, competitive strategies, and innovative pipeline developments, revealing the competitive intensity and future market trajectory.
• Growth Drivers and Market Trends: Exploration of the key factors driving market growth, such as the rising prevalence of shingles, increasing geriatric population, and growing awareness of the benefits of vaccination, alongside an examination of emerging market trends and their potential impact.
• Regional Market Analysis: A detailed analysis of regional markets and their varying growth rates, highlighting factors affecting market growth in each region, including regulatory environment, healthcare infrastructure, and public health initiatives.
• Technological Advancements and Innovation: Assessment of the latest technological advancements in shingles vaccine development, including novel vaccine formulations and delivery methods, and their potential to enhance vaccine efficacy and accessibility.
• Future Outlook and Projections: Presentation of a comprehensive forecast of the shingles vaccine market, considering anticipated market drivers, challenges, and technological advancements, providing stakeholders with informed decision-making tools.

Regional Insight

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Pricing Analysis

• Analysis of the pricing trends and strategies of the leading players in the market
• Impact of pricing on market share and profitability
• Analysis of the factors influencing pricing decisions

Import And Export Analysis

• Analysis of the import and export trends and patterns of shingles vaccines
• Major importing and exporting countries
• Analysis of the factors influencing import and export

Patent/Trademark Analysis

• Analysis of the patent and trademark landscape of the shingles vaccine market
• Identification of the key patents and trademarks
• Analysis of the impact of patents and trademarks on market dynamics